From the Guidelines
Hormone Replacement Therapy (HRT) can be considered for a 60-year-old postmenopausal woman, with her last menstrual period 12 years ago, according to Canadian guidelines, but with caution and individualized assessment of benefits and risks. The Canadian Menopause Society supports HRT for women within 10 years of menopause or under age 60 who have vasomotor symptoms, with the benefits typically outweighing risks 1. For this patient, a low-dose regimen would be appropriate, such as oral estradiol 0.5mg daily or transdermal estradiol patch 0.025-0.0375mg/day, along with progesterone 100mg daily if she has an intact uterus.
Key Considerations
- Before starting treatment, conduct a thorough risk assessment including breast cancer, cardiovascular disease, and venous thromboembolism history 1.
- A baseline mammogram and cardiovascular risk assessment are recommended.
- Start with the lowest effective dose and reassess annually, discussing the benefits (symptom relief, potential bone protection) versus risks (slightly increased risk of breast cancer with long-term use, blood clots) 1.
Individualized Approach
The therapy should be individualized based on her specific symptoms, preferences, and risk factors.
- The patient's quality of life and health priorities should be taken into account when making the decision to use HRT.
- The North American Menopause Society advocates that individualization is of key importance in the decision to use hormone therapy and that it should incorporate women's health and quality-of-life priorities, as well as such personal risk factors as risk for venous thrombosis, CHD, stroke, and breast cancer 1.